Inside of Ambulance-1 (1)
SurgiBox Announces Strategic Partnership with Accord International to Expand into Japanese Market
17 nov. 2024 18h17 HE | SurgiBox
TOKYO, Nov. 17, 2024 (GLOBE NEWSWIRE) -- SurgiBox Inc., a leader in portable surgical solutions, is thrilled to announce a strategic partnership with Japanese medical distribution company, Accord...
Kane Logo Cropped TransBG.png
Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel
14 nov. 2024 13h10 HE | Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21
14 nov. 2024 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Third Quarter 2024 Financial Results
13 nov. 2024 16h01 HE | electroCore, Inc.
Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales  Company to host a conference call and webcast today, November 13, 2024 at...
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™,  A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
Acuitive Technologies Receives FDA 510(k) Clearance for CITREPORE™, A New Synthetic Bioactive Bone Void Filler for Orthopedic Procedures
12 nov. 2024 08h00 HE | Acuitive Technologies
Acuitive Technologies announced the FDA 510(k) clearance of CITREPORE™, a new synthetic bioactive bone void filler for orthopedic procedures.
Logo 1200x628.jpg
CytoSorbents Reports Third Quarter 2024 Financial and Operational Results
07 nov. 2024 16h05 HE | CytoSorbents
PRINCETON, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
R3 Vascular Logo.jpg
FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial of its MAGNITUDE® Drug Eluting Next Generation Bioresorbable Scaffold for Below-the-Knee Peripheral Arterial Disease
04 nov. 2024 06h00 HE | R3 Vascular
MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
23 oct. 2024 08h00 HE | electroCore, Inc.
ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
Logo 1200x628.jpg
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22 oct. 2024 07h00 HE | CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
Logo.png
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference
18 oct. 2024 08h00 HE | Helius Medical Technologies, Inc.
Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference